Innovative therapeutics with a de-risk approach
PurMinds is a neuropharma company operating out of a neuro lab and production facility in Ontario, Canada. We develop novel therapeutics to address unmet medical needs by combining proven mechanism of action with cutting-edge discoveries in psychedelic research to accelerate drug development.
PurMinds owns and operates a portfolio of technical assets and special licenses that give the Company a competitive edge. We de-risk our enterprise portfolio by developing revenue-generating global API supply of both generic compounds and proprietary formulations.
Our team has the shared vision of solving complex medical problems that have a real and devastating impact on people close to us and around the world. It's what drives us. We are visionaries that strive to make our work really matter, and we measure our success by the advancement of our therapeutics that can help those in need.
President & Chief Executive Officer
A serial entrepreneur and strategic visionary with 15+ years of corporate banking experience and 8+ years of strategic management and business development work in investment, biotech and branding marketing field.
Chief Scientific Officer
Dr. Kozikowski is a Global leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience. He worked as a Professor for over 40 years at a number of prestigious universities in the field of medicinal chemistry, and is known for his research on 5-HT receptors, HDAC and GSK-3 inhibitors, and has over 100 patents and over 550 publications.
Chief Innovation Officer
A recognized leader in neuroscience and neuropharmacology; specializing in psychedelic clinical development, neurodegeneration, and nutritional neurobiology; with 15 years of expertise in translational medicine spanning from molecules to mind
Chief Financial Officer &
Chief Operating Officer
Senior Financial Leader with 30+ years experience in FP&A, Business Valuation, general accounting, risk management, and in driving financial and operational excellence.
Vice President, NeuroLabs
Over 25 years of experience in laboratory operation and management, scientific research team leadership in chemistry, multi-omics for biomarker based precision medicine.
Vice President, Technology
Strong science background with extensive experience in research and development for laboratory and production technology. Ms. Kim plays a key role in the advancement of PurMinds botanical production process, and is desired to support the development of new therapies for devastating neurological diseases.
Co-Principal Investigator of Psychedelic clinical trials and adjunct teaching faculty in Johns Hopkins University.
Director, Quality and
With extensive experience and a long track-record in quality assurance and regulatory affairs, Mr. Wallace is helping Purminds navigate the regulatory framework of Health Canada, the US FDA and the European Medicines Agency (EMA).
Scientific Advisory Board
Professor of Neurobiology
Brain Research Center
Southern University of Science and Technology (SUSTech)
University of Ottawa Health Services
Queensland Brain Institute
The University of Queensland (UQ)
SUSTech-UQ Joint Center for Neuroscience & Neural Engineering
registered to act before the Canadian and United States Patent Offices, with specialties in biochemistry, organic chemistry, biotechnology, pharmaceutical inventions, food science, medical devices, simple mechanics and business methods
BENOÎT & CÔTÉ,